Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated